Related Experiment Video
Updated: Sep 22, 2025
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
26.0K
Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
Angeliki Bourazana1, Grigorios Giamouzis1, John Skoularigis1
1Department of Cardiology, University Hospital of Larissa, Larissa 41110, Greece.
World Journal of Cardiology
|May 18, 2022
Summary
Dipeptidyl peptidase-4 (DPP-4) inhibitors effectively manage blood glucose in type 2 diabetes. However, studies show these drugs have a neutral effect on major cardiovascular outcomes in diabetic patients.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus (DM) is linked to diverse heart failure phenotypes, including structural and electrical cardiac remodeling.
- Diabetic cardiomyopathy presents a spectrum from subclinical abnormalities to severe biventricular dysfunction and increased mortality.
- Type 2 DM affects millions globally, necessitating effective management strategies for both glycemic control and cardiovascular health.
Purpose of the Study:
- To evaluate the cardiovascular outcomes of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes.
- To assess the impact of DPP-4 inhibitors on myocardial infarction, stroke, heart failure hospitalizations, and cardiovascular death.
- To investigate the potential association between DPP-4 inhibitor use and atrial flutter in diabetic patients.
Main Methods:
- Review of clinical data and studies investigating DPP-4 inhibitors in type 2 diabetes.
- Analysis of cardiovascular event rates, including myocardial infarction, stroke, and heart failure hospitalizations.
- Exploration of cardiac electrical remodeling and potential links to atrial flutter in the context of DPP-4 inhibitor therapy.
Main Results:
- DPP-4 inhibitors demonstrate efficacy in lowering blood glucose levels by enhancing incretin hormone activity.
- The cardiovascular outcomes associated with DPP-4 inhibitor use in diabetic patients have been found to be neutral.
- No significant impact was observed on major adverse cardiovascular events such as myocardial infarction, stroke, or cardiovascular death.
Conclusions:
- DPP-4 inhibitors are a safe and effective glucose-lowering option for type 2 diabetes, but do not confer cardiovascular benefits.
- Further research is warranted to explore the relationship between DPP-4 inhibitors and atrial flutter in the diabetic population.
- While managing hyperglycemia, DPP-4 inhibitors do not appear to alter the cardiovascular risk profile in patients with diabetes.
Keywords:
Atrial flutterDiabetes mellitusDipeptidyl peptidase-4 inhibitorsHeart failureMeta-analysisOutcomesMore Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
388
10:35Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
2.9K
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
315
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
315
01:15Diabetes: Management and Pharmacotherapy
420
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
420
01:36Carbohydrate Metabolism
11.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.9K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
288
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
288
01:22Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K